RxDoctor Payments Data

Sherif Dimyan

Neurology · Gardena, CANPI 1770680225

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (52.1%), food and beverage and education — rather than concentrated in one kind of arrangement. AbbVie accounts for 76.3% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2021 at $5,741 and has fallen 93.2% since, to $388 in 2022.

$7,629in general payments, 2019–2025

Across 167 payments — averaging $45.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$6K
  • AstraZeneca$329
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$257
  • Vanda Pharmaceuticals Inc.$241
  • UCB, Inc.$216
  • Scilex Pharmaceuticals Inc.$144
  • plus $623 from 14 others

What the payments were for

  • Speaking & faculty fees$3,97552%
  • Food & beverage$3,60747%
  • Education$471%

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,629 in reported general payments places this provider in the 70th percentile of 1,996 neurology providers in California.

See all neurology providers in California →

Other neurology in Gardena

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →